Health Care [ 3/12 ] | Pharmaceuticals [ 9/73 ]
NASDAQ | Common Stock
Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases.
It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers.
Evoke Pharma, Inc. was incorporated in 2007 and is based in Solana Beach, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 10, 25 | -0.45 Increased by +52.13% | -0.45 |
| Aug 14, 25 | -0.62 Increased by +33.29% | -0.30 Decreased by -106.67% |
| May 12, 25 | -0.51 Decreased by -200.00% | -0.33 Decreased by -54.55% |
| Mar 12, 25 | -0.77 Decreased by -30.51% | -0.63 Decreased by -22.22% |
| Nov 7, 24 | -0.94 Decreased by -84.31% | -0.38 Decreased by -147.37% |
| Aug 8, 24 | -0.93 Decreased by -65.96% | -0.72 Decreased by -29.08% |
| May 14, 24 | -0.17 Increased by +74.63% | -0.21 Increased by +19.05% |
| Mar 14, 24 | -0.59 Decreased by -11.32% | -0.50 Decreased by -18.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 4.28 M Increased by +61.40% | -1.16 M Increased by +11.90% | Decreased by -26.99% Increased by +45.42% |
| Jun 30, 25 | 3.75 M Increased by +47.06% | -1.57 M Decreased by -23.97% | Decreased by -41.87% Increased by +15.70% |
| Mar 31, 25 | 3.08 M Increased by +77.48% | -1.31 M Increased by +17.32% | Decreased by -42.41% Increased by +53.42% |
| Dec 31, 24 | 3.31 M Increased by +97.40% | -1.19 M Increased by +39.98% | Decreased by -36.05% Increased by +69.60% |
| Sep 30, 24 | 2.65 M Increased by +69.83% | -1.31 M Increased by +22.52% | Decreased by -49.45% Increased by +54.38% |
| Jun 30, 24 | 2.55 M Increased by +125.51% | -1.27 M Increased by +32.16% | Decreased by -49.67% Increased by +69.92% |
| Mar 31, 24 | 1.74 M Increased by +114.15% | -1.58 M Increased by +29.57% | Decreased by -91.03% Increased by +67.11% |
| Dec 31, 23 | 1.68 M Increased by +110.45% | -1.99 M Decreased by -10.21% | Decreased by -118.58% Increased by +47.63% |